Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Maintenance Dose Schedule and Treatment Setting: Pilot
NCT00000318Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- Dec 1994
- Primary completion
- Mar 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2 trial of buprenorphine in opioid use disorder (OUD) and substance-related disorders (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Opioid and cocaine use at 26 weeks, Social and psychological functioning at 26 weeks and 1 more. Started Dec 1994; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)substance-related disorders
Beyond the preview
Go deeper on NCT00000318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000318.